You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
McKesson
Harvard Business School
Moodys
AstraZeneca

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,506,929

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,506,929 protect, and when does it expire?

Patent 8,506,929 protects AMYVID and is included in one NDA.

This patent has forty-eight patent family members in thirty-two countries.

Summary for Patent: 8,506,929
Title:Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Abstract: This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.
Inventor(s): Kung; Hank F. (Wynnewood, PA), Kung; Mei-Ping (Wynnewood, PA)
Assignee: The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:12/186,072
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 8,506,929

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-001 Apr 6, 2012 DISCN No No   Start Trial   Start Trial Y Y AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT   Start Trial
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-002 Apr 6, 2012 RX Yes Yes   Start Trial   Start Trial Y Y AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT   Start Trial
Avid Radiopharms Inc AMYVID florbetapir f-18 SOLUTION;INTRAVENOUS 202008-003 Apr 6, 2012 RX Yes Yes   Start Trial   Start Trial Y Y AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Mallinckrodt
McKesson
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.